Q3 EPS Estimates for Belite Bio Decreased by Leerink Partnrs

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Belite Bio in a report released on Monday, August 11th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($0.54) per share for the quarter, down from their prior estimate of ($0.46). The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Belite Bio’s Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.05) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at $0.95 EPS and FY2028 earnings at $6.70 EPS.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.03). During the same period in the previous year, the business posted ($0.31) earnings per share.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Belite Bio in a research report on Thursday, July 3rd. Wall Street Zen cut Belite Bio from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Belite Bio in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $96.67.

Belite Bio Stock Performance

NASDAQ:BLTE opened at $66.63 on Thursday. The company has a market capitalization of $2.12 billion, a P/E ratio of -42.99 and a beta of -1.49. The stock’s 50 day moving average price is $62.77 and its 200 day moving average price is $61.61. Belite Bio has a 52 week low of $43.70 and a 52 week high of $86.53.

Institutional Investors Weigh In On Belite Bio

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of Belite Bio by 43.3% in the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company’s stock valued at $122,000 after acquiring an additional 559 shares during the period. EverSource Wealth Advisors LLC bought a new stake in shares of Belite Bio in the second quarter valued at approximately $147,000. BNP Paribas Financial Markets bought a new stake in shares of Belite Bio in the fourth quarter valued at approximately $155,000. XTX Topco Ltd boosted its position in shares of Belite Bio by 30.9% in the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company’s stock valued at $446,000 after acquiring an additional 1,668 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Belite Bio in the second quarter valued at approximately $547,000. Institutional investors own 0.53% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.